Elaine Chen , 2025-04-29 20:01:00
BridgeBio’s recently approved heart drug brought in $36.7 million in sales in the first quarter, blowing past expectations as the biotech continues to see a strong demand for its first major commercial product.
Analysts had estimated that the treatment, called Attruby, would bring in sales of $12 million, but Wall Street’s “whisper number” was $17 million to $20 million.
Between the approval of the treatment last November and the end of the last week, over 750 health care providers have written more than 2,000 patient prescriptions, BridgeBio said while reporting earnings Tuesday. Analysts estimated about 1,700 prescriptions through the first quarter.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.
